(Q38048606)

27 August 2017

title

Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. (English)

1 reference

27 August 2017

0 references

Andrew S Bomback

1

1 reference

27 August 2017

Gerald B Appel

series ordinal

2

1 reference

27 August 2017

language of work or name

English

0 references

publication date

2 October 2012

1 reference

Nature Reviews Nephrology

27 August 2017

published in

1 reference

27 August 2017

volume

8

1 reference

27 August 2017

issue

11

1 reference

27 August 2017

page(s)

634-642

1 reference

Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone--a report of the International Study of Kidney Disease in Children

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

C3 glomerulopathy: a new classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Immunopathology of membranoproliferative glomerulonephritis with subendothelial deposits (Type I MPGN)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Dense deposit disease: a variant of membranoproliferative glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Membranoproliferative glomerulonephritis--a new look at an old entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Dense deposit disease is not a membranoproliferative glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

C3 glomerulopathy: what's in a name?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Alternative complement pathway assessment in patients with atypical HUS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Causes of alternative pathway dysregulation in dense deposit disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Pathology after eculizumab in dense deposit disease and C3 GN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Hypocomplementemia of membranoproliferative nephritis. Dependence of the nephritic factor reaction on properdin factor B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

A serum factor in chronic hypocomplementemic hephritis distinct from immunoglobulins and activating the alternate pathway of complement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Nephritic factors predispose to chronic glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Eculizumab for dense deposit disease and C3 glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Complement and glomerular disease: new insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Membranoproliferative glomerulonephritis type II (dense deposit disease): an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Eculizumab and Refractory Membranoproliferative Glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

New approaches to the treatment of dense deposit disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Autoimmune forms of thrombotic microangiopathy and membranoproliferative glomerulonephritis: Indications for a disease spectrum and common pathogenic principles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Atypical hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Complement factor H deficiency and posttransplantation glomerulonephritis with isolated C3 deposits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Three kidneys, two diseases, one antibody?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

21 January 2018

Dense deposit disease.

2 references

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

21 January 2018

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

7 January 2021

inferred from DOI database lookup

The role of complement and its receptor in the elimination of immune complexes

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Complement factor H deficiency accelerates development of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Dense Deposit Disease Associated With Monoclonal Gammopathy of Undetermined Significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Eculizumab for the Treatment of Dense-Deposit Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Eculizumab in a patient with dense-deposit disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Recurrent glomerular diseases after renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Complement inhibitor eculizumab in atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

C3 deposition glomerulopathy due to a functional factor H defect

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Composition of nephritic factor-generated glomerular deposits in membranoproliferative glomerulonephritis type 2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

The Complement Abnormalities of Lipodystrophy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Combined C3b and factor B autoantibodies and MPGN type II

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Mouse podocyte complement factor H: the functional analog to human complement receptor 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

C3 glomerulopathy masquerading as acute postinfectious glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Recurrent membranoproliferative glomerulonephritis after kidney transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Recurrent type I membranoproliferative glomerulonephritis in a renal allograft: successful treatment with plasmapheresis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.213

Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis

31 March 2020

1 reference

12 December 2020

Hypocomplementaemia of poststreptococcal acute glomerulonephritis is associated with C3 nephritic factor (C3NeF) IgG autoantibody activity

1 reference

12 December 2020

C3 nephritic factor and hypocomplementaemia in a clinically healthy individual

1 reference

12 December 2020

Membranoproliferative glomerulonephritis with disruption of the glomerular basement membrane

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2012.213

1 reference

27 August 2017

1 reference